Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.81 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.69 |
| ▸ | CCR7 | P32248 | 1/20 | 0.56 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482409 | 0.90 | CXCR2 (0.80) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL4475954 | 0.90 | CXCR2 (1.00) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL4483211 | 0.88 | CXCR2 (0.77) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL841656 | 0.83 | CXCR2 (0.81) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL6869113 | 0.82 | CXCR2 (0.80) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL842193 | 0.82 | CXCR2 (1.00) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL2905264 | 0.81 | CXCR2 (0.71) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL842950 | 0.80 | CXCR2 (0.77) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL4693395 | 0.80 | CXCR2 (0.70) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL6865142 | 0.80 | CXCR2 (0.77) | CXCR2CXCR1CCR7CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306262-A1 | Novel Compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885CXCR1 274/4885CCR7 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.